Akums unveils Rabeprazole plus Levosulpiride SR Capsules for GERD in India

GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer.

Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology.

Speaking about the launch, Ms Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd., commented, “We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients' overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience."

Sandeep Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., added, “The first step to curing any ailment is awareness. It's crucial to raise awareness about GERD to mitigate the risk of developing this condition. The introduction of Rabeprazole + Levosulpiride SR Capsules shows Akums' commitment to providing effective pharmaceutical solutions that cater to unmet medical needs. We are optimistic that this novel formulation will make a meaningful difference in the lives of patients. I must appreciate the efforts of our R&D team that has helped in bringing this formulation.”

Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.